<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458445</url>
  </required_header>
  <id_info>
    <org_study_id>SPD465-311</org_study_id>
    <nct_id>NCT00458445</nct_id>
  </id_info>
  <brief_title>A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators</brief_title>
  <official_title>A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With SPD465 Compared to Placebo on Simulated Driving Safety and Performance in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether SPD465 is safe and effective in the
      treatment of ADHD in young adult drivers after a duration of 16 hours.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study was stopped by the sponsor before enrollment based on a non-safety related corporate
    decision.
  </why_stopped>
  <start_date>April 2007</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Driver Safety (DS) Score averaged over 3 driving assessments at one interim and one final visit.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Simulated DS scores &amp; individual components, averaged over the testing times. Interim &amp; final visits: ADHD-RS-IV, CGI-I and Self-Rating of DS Performance Questionnaire. TEAEs, vital signs, lab parameters, physical exams &amp; ECG measurements.</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD465</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have a valid driver's license with a minimum of 3 years of driving
             experience.

          2. Subject reports daily driving activity.

          3. Subject is fluent in English.

          4. Subject must be male or non-pregnant, non-lactating female who agrees to comply with
             any applicable contraceptive requirements of the protocol.

          5. Subject must have a satisfactory medical assessment with no clinically significant or
             relevant abnormalities

          6. Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD) established by a
             comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria

        Exclusion criteria:

          1. Subject is significantly underweight or morbidly obese.

          2. Subject has a controlled (requiring a restricted medication) or uncontrolled, comorbid
             psychiatric diagnosis with significant symptoms such as Post Traumatic Stress Disorder
             (PTSD), psychosis, bipolar illness, severe obsessive compulsive disorder, severe
             depressive or severe anxiety disorder or other symptomatic manifestations that, in the
             opinion of the examining Physician, will contraindicate SPD465 treatment or confound
             efficacy or safety assessments.

          3. Subject with a lifetime history of psychosis or bipolar disorder.

          4. Subject with any concurrent chronic or acute illness or unstable medical condition,
             either treated or untreated.

          5. Subject with a history of mental retardation or a severe learning disability.

          6. Subject is na√Øve to ADHD treatment with methylphenidate or amphetamine.

          7. Subject has a history of glaucoma or narrow angle glaucoma.

          8. Subject has a history of seizure (other than infantile febrile seizures), any tic
             disorder, or a current diagnosis and/or family history of Tourette's Disorder.

          9. Subject has known cardiac structural abnormalities as well as any other condition that
             may affect cardiac performance.

         10. Subject has clinically significant ECG or laboratory abnormalities at Screening or
             Baseline.

         11. Subject has a history of hypertension or has a resting sitting systolic blood pressure
             &gt;139mmHg or diastolic blood pressure &gt;89mmHg10.

         12. Subject has used any psychoactive prescription medication or over-the-counter (OTC)
             medication requiring more than a 28-day washout. Hormonal contraceptives are
             acceptable.

         13. Subject has a documented allergy, intolerance, or documented history of
             non-responsivity to amphetamine.

         14. Subject currently has (or had a history within the last 6 months) a substance use
             disorder (excluding nicotine).

         15. Subject has taken another investigational drug or taken part in a clinical trial
             within the last 30 days prior to Screening.

         16. Female subject is pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Huffman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meridien Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2007</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <name_title>Timothy Whitaker, M.D.</name_title>
    <organization>Shire Pharmaceutical</organization>
  </responsible_party>
  <keyword>Attention-Deficit Hyperactivity Disorder (ADHD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

